Stock analysts at HC Wainwright started coverage on shares of Xilio Therapeutics (NASDAQ:XLO) in a research note issued on Monday, Analyst Price Targets reports. The firm set a “buy” rating on the stock.
A number of other research analysts also recently commented on the stock. Morgan Stanley assumed coverage on shares of Xilio Therapeutics in a research report on Tuesday, November 16th. They set an “overweight” rating and a $32.00 target price on the stock. Raymond James assumed coverage on shares of Xilio Therapeutics in a research report on Tuesday, November 16th. They set an “outperform” rating and a $31.00 target price on the stock. Cowen assumed coverage on shares of Xilio Therapeutics in a research report on Tuesday, November 16th. They set an “outperform” rating on the stock. Finally, Guggenheim assumed coverage on shares of Xilio Therapeutics in a research report on Tuesday, November 16th. They set a “buy” rating on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $31.50.
XLO traded up $0.48 on Monday, reaching $14.80. 26,437 shares of the company traded hands, compared to its average volume of 49,398. Xilio Therapeutics has a one year low of $8.52 and a one year high of $27.95. The firm has a fifty day moving average price of $16.89.
Xilio Therapeutics (NASDAQ:XLO) last announced its quarterly earnings data on Wednesday, December 1st. The company reported ($21.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($19.67). Equities analysts predict that Xilio Therapeutics will post -5.64 EPS for the current year.
In related news, major shareholder Rock Springs Capital Managemen bought 500,000 shares of the company’s stock in a transaction on Tuesday, October 26th. The shares were bought at an average price of $16.00 per share, with a total value of $8,000,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Bain Capital Life Sciences Inv bought 13,458 shares of the company’s stock in a transaction on Wednesday, December 8th. The shares were bought at an average cost of $9.62 per share, for a total transaction of $129,465.96. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 538,458 shares of company stock worth $8,370,716.
Xilio Therapeutics Company Profile
Xilio Therapeutics Inc is a biotechnology company which focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company’s product candidate includes XTX101, XTX202, XTX301 and XTX401 which are in clinical stage. Xilio Therapeutics Inc is based in WALTHAM, Mass.